publicationMetadata:
  pmid: "29982664"
  title: "EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma."
  queryType: "bench,clinical"
  publicationType: "Lab Research"
  publicationTypeConfidence: 0.95
  hasMethodsSection: Yes
  likelyContainsTools: Yes
  expectedToolTypes: |
    Lab Research â†’ antibodies, cell lines, animal models, genetic reagents, computational tools, organoids, PDX
    
    This is a laboratory research study investigating EPH receptor signaling in NF2-deficient meningioma.
    The methods describe high-throughput kinome analyses, immunoblotting, cell-based drug screening,
    and orthotopic animal models. This type of study would typically use:
    - Cell lines (NF2-null human arachnoidal and meningioma cell lines mentioned)
    - Animal models (orthotopic meningioma model mentioned)
    - Antibodies (for immunoblotting and kinome analyses)
    - Computational tools (for high-throughput kinome analyses)
    - Genetic reagents (potentially for creating NF2-null cells)
  overallAssessment: |
    This is a clear laboratory research study with experimental methods including cell culture,
    immunoblotting, drug screening, and animal models. The publication should contain multiple
    research tools including cell lines, antibodies, animal models, and computational tools.
    The fact that 0 tools were mined suggests significant gaps in the mining patterns.

toolValidations: []

potentiallyMissedTools:
  - toolName: "NF2-null human arachnoidal cell lines"
    toolType: "cell_line"
    foundIn: "methods"
    contextSnippet: "High-throughput kinome analyses were performed in NF2-null human arachnoidal and meningioma cell lines to identify functional kinome changes upon NF2 loss."
    whyMissed: "Cell line description was not recognized - may need patterns for 'NF2-null' or 'gene-null' cell line nomenclature"
    confidence: 0.9
    shouldBeAdded: Yes

  - toolName: "NF2-null human meningioma cell lines"
    toolType: "cell_line"
    foundIn: "methods"
    contextSnippet: "High-throughput kinome analyses were performed in NF2-null human arachnoidal and meningioma cell lines to identify functional kinome changes upon NF2 loss."
    whyMissed: "Cell line description was not recognized - may need patterns for 'NF2-null' or 'gene-null' cell line nomenclature"
    confidence: 0.9
    shouldBeAdded: Yes

  - toolName: "orthotopic meningioma model"
    toolType: "animal_model"
    foundIn: "methods"
    contextSnippet: "Antitumor drug efficacy was tested in an orthotopic meningioma model."
    whyMissed: "Animal model description was not recognized - may need patterns for 'orthotopic model' terminology"
    confidence: 0.85
    shouldBeAdded: Yes

  - toolName: "dasatinib"
    toolType: "genetic_reagent"
    foundIn: "results"
    contextSnippet: "Dasatinib significantly inhibited phospho-EPH receptor A2 (pEPHA2), pEPHB1, c-KIT, and Src/SFK in NF2-null cells"
    whyMissed: "Drug/compound used as experimental reagent was not recognized - may need patterns for kinase inhibitors"
    confidence: 0.8
    shouldBeAdded: Yes

  - toolName: "dual mTORC1/2 inhibitor"
    toolType: "genetic_reagent"
    foundIn: "results"
    contextSnippet: "While dasatinib treatment showed some activity, dual mTORC1/2 inhibitor and its combination with dasatinib elicited stronger growth inhibition"
    whyMissed: "Drug/compound used as experimental reagent was not recognized - may need patterns for mTOR inhibitors"
    confidence: 0.8
    shouldBeAdded: Yes

suggestedPatterns:
  - patternType: "naming_convention"
    pattern: "[A-Z0-9]+-null.*cell line[s]?"
    toolType: "cell_line"
    examples: ["NF2-null human arachnoidal cell lines", "NF2-null human meningioma cell lines"]
    reasoning: "Gene knockout cell lines often use 'gene-null' nomenclature that wasn't captured by existing patterns"

  - patternType: "context_phrase"
    pattern: "orthotopic.*model"
    toolType: "animal_model"
    examples: ["orthotopic meningioma model"]
    reasoning: "Orthotopic models are common in cancer research but may not be captured by current animal model patterns"

  - patternType: "term"
    pattern: "dasatinib|imatinib|nilotinib|bosutinib"
    toolType: "genetic_reagent"
    examples: ["dasatinib"]
    reasoning: "Tyrosine kinase inhibitors are commonly used research reagents but may not be captured as tools"

  - patternType: "context_phrase"
    pattern: "mTORC?[12]/? inhibitor"
    toolType: "genetic_reagent"
    examples: ["dual mTORC1/2 inhibitor"]
    reasoning: "mTOR pathway inhibitors are common research reagents that should be captured"

  - patternType: "context_phrase"
    pattern: "high-throughput.*analys[ie]s"
    toolType: "computational_tool"
    examples: ["High-throughput kinome analyses"]
    reasoning: "High-throughput analyses typically require specialized computational tools/platforms"

  - patternType: "context_phrase"
    pattern: "immunoblotting|western blot"
    toolType: "antibody"
    examples: ["Immunoblotting confirmed the activation of kinases"]
    reasoning: "Immunoblotting mentions should trigger search for specific antibodies used"

observations:
  - resourceName: "NF2-null human arachnoidal cell lines"
    resourceType: "Cell Line"
    observationType: "Cellular"
    observationTypeOntologyId: "MP:0005384"
    details: |
      NF2-null cells showed activation of EPH receptor tyrosine kinases (EPH RTKs), c-KIT, and Src family kinase (SFK) members.
      These kinases were among the top candidates activated upon NF2 loss based on high-throughput kinome analyses.
    foundIn: "results"
    contextSnippet: "Erythropoietin-producing hepatocellular receptor tyrosine kinases (EPH RTKs), c-KIT, and Src family kinase (SFK) members, which are biological targets of dasatinib, were among the top candidates activated in NF2-null cells."
    confidence: 0.9
    doi: "10.1093/neuonc/noy046"

  - resourceName: "NF2-null human meningioma cell lines"
    resourceType: "Cell Line"
    observationType: "Cellular"
    observationTypeOntologyId: "MP:0005384"
    details: |
      NF2-null meningioma cells showed activation of EPH receptor tyrosine kinases, c-KIT, and Src family kinases.
      Dasatinib treatment significantly inhibited phospho-EPH receptor A2 (pEPHA2), pEPHB1, c-KIT, and Src/SFK in these cells.
      Dual mTORC1/2 inhibitor and its combination with dasatinib elicited stronger growth inhibition.
    foundIn: "results"
    contextSnippet: "Dasatinib significantly inhibited phospho-EPH receptor A2 (pEPHA2), pEPHB1, c-KIT, and Src/SFK in NF2-null cells, showing no cross-talk with mTORC1/2 signaling."
    confidence: 0.9
    doi: "10.1093/neuonc/noy046"

  - resourceName: "orthotopic meningioma model"
    resourceType: "Animal Model"
    observationType: "Tumor Growth"
    observationTypeOntologyId: "MP:0002006"
    details: |
      The orthotopic meningioma model was used to test antitumor drug efficacy.
      This model allowed evaluation of drug treatments in vivo for meningioma research.
    foundIn: "methods"
    contextSnippet: "Antitumor drug efficacy was tested in an orthotopic meningioma model."
    confidence: 0.8
    doi: "10.1093/neuonc/noy046"

  - resourceName: "dasatinib"
    resourceType: "Genetic Reagent"
    observationType: "Usage Instructions"
    observationTypeOntologyId: ""
    details: |
      Dasatinib significantly inhibited phospho-EPH receptor A2 (pEPHA2), pEPHB1, c-KIT, and Src/SFK in NF2-null cells.
      Treatment showed some growth inhibitory activity but was more effective when combined with mTORC1/2 inhibitor.
      No cross-talk was observed with mTORC1/2 signaling pathways.
    foundIn: "results"
    contextSnippet: "Dasatinib significantly inhibited phospho-EPH receptor A2 (pEPHA2), pEPHB1, c-KIT, and Src/SFK in NF2-null cells, showing no cross-talk with mTORC1/2 signaling."
    confidence: 0.85
    doi: "10.1093/neuonc/noy046"

  - resourceName: "dual mTORC1/2 inhibitor"
    resourceType: "Genetic Reagent"
    observationType: "Usage Instructions"
    observationTypeOntologyId: ""
    details: |
      Dual mTORC1/2 inhibitor elicited stronger growth inhibition in meningiomas compared to dasatinib alone.
      The combination of mTORC1/2 inhibitor with dasatinib showed enhanced efficacy for growth inhibition.
      Co-targeting mTORC1/2 and EPH RTK/SFK pathways represents a novel effective treatment strategy.
    foundIn: "results"
    contextSnippet: "While dasatinib treatment showed some activity, dual mTORC1/2 inhibitor and its combination with dasatinib elicited stronger growth inhibition in meningiomas."
    confidence: 0.85
    doi: "10.1093/neuonc/noy046"

summary:
  totalToolsMined: 0
  toolsAccepted: 0
  toolsRejected: 0
  toolsUncertain: 0
  potentiallyMissedCount: 5
  newPatternsCount: 6
  observationsExtracted: 5
  observationsByType:
    Cellular: 2
    Tumor Growth: 1
    Usage Instructions: 2
  majorIssuesFound: |
    - Complete failure of mining system to detect any tools in a clear laboratory research paper
    - Cell lines with gene knockout nomenclature (NF2-null) were not recognized
    - Animal models described as "orthotopic model" were not captured
    - Drug compounds used as experimental reagents (dasatinib, mTORC1/2 inhibitor) were missed
    - High-throughput analyses mentioned but no computational tools identified
    - Immunoblotting mentioned but no antibodies captured
  recommendations: |
    This publication represents a significant mining failure - 0 tools were found in a clear laboratory
    research study that should contain multiple tool types. The following tools should definitely be added:
    - NF2-null human arachnoidal and meningioma cell lines (high confidence)
    - Orthotopic meningioma animal model (high confidence)
    - Dasatinib and mTORC1/2 inhibitor as experimental reagents (high confidence)
    
    The mining patterns need significant improvement to capture:
    - Gene knockout cell line nomenclature (gene-null format)
    - Orthotopic animal model terminology
    - Drug compounds used as research reagents
    - High-throughput analysis platforms
    - Immunoblotting-related antibodies
    
    This paper demonstrates clear gaps in the current mining approach for laboratory research tools.
    All 5 potentially missed tools should be manually reviewed and likely added to improve coverage.
